Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03379649 · ClinicalTrials.gov registry record · Early Phase 1
Platelet Rich Plasma for Patients With Recurrent Implantation Failure
A Early Phase 1 study, sponsored by Stanford University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 50
- Enrollment target
NCT03379649: Completed Early Phase 1 study, sponsored by Stanford University.
NCT03379649 is a Early Phase 1 study that has completed, run by Stanford University. The registered enrollment target is 50 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03379649, a Early Phase 1 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
Patients with recurrent implantation failure are among the most difficult patients to treat, with no proven standard treatment. Platelet rich plasma stimulates cellular processes involved in endometrial regeneration, and in a small case series has shown efficacy for this patient population. We hope to conduct a randomized controlled pilot study to determine whether PRP is indeed an effective treatment for recurrent implantation failure.
Interventions
- COMBINATION_PRODUCT Placebo
- COMBINATION_PRODUCT Platelet rich plasma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2019-01-16 |
| Est. Completion | 2023-12-20 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03379649
The ClinicalTrials.gov registry entry for NCT03379649 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03379649 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03379649 about?
NCT03379649 is a clinical study titled "Platelet Rich Plasma for Patients With Recurrent Implantation Failure". Patients with recurrent implantation failure are among the most difficult patients to treat, with no proven standard treatment. Platelet rich plasma stimulates cellular processes involved in endometrial regeneration, and in a small case series has shown efficacy for this patient population. We hope ...
What is the current status of trial NCT03379649?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 50 participants. The study started on 2019-01-16. Estimated completion is 2023-12-20.
What interventions are being tested in trial NCT03379649?
The interventions under investigation include: Placebo (COMBINATION_PRODUCT), Platelet rich plasma (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT03379649?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.